OBJECTIVES: We assessed recent (1992-1997) HIV incidence in the large HIV epidemic among injection drug users in New York City. METHODS: Data were compiled from 10 separate studies (N = 4979), including 6 cohort studies, 2 "repeat service user" studies, and 2 analyses of voluntary HIV testing and counseling services within drug treatment programs. RESULTS: In the 10 studies, 52 seroconversions were found in 6344 person-years at risk. The observed incidence rates among the 10 studies were all within a narrow range, from 0 per 100 person-years at risk to 2.96 per 100 person-years at risk. In 9 of the 10 studies, the observed incidence rate was less than 2 per 100 person-years at risk. The weighted average incidence rate was 0.7 per 100 person-years at risk. CONCLUSIONS: The recent incidence rate in New York City is quite low for a high-seroprevalence population of injection drug users. The very large HIV epidemic among injection drug users in New York City appears to have entered a "declining phase," characterized by low incidence and declining prevalence. The data suggest that very large high-seroprevalence HIV epidemics may be "reversed."
OBJECTIVES: We assessed recent (1992-1997) HIV incidence in the large HIV epidemic among injection drug users in New York City. METHODS: Data were compiled from 10 separate studies (N = 4979), including 6 cohort studies, 2 "repeat service user" studies, and 2 analyses of voluntary HIV testing and counseling services within drug treatment programs. RESULTS: In the 10 studies, 52 seroconversions were found in 6344 person-years at risk. The observed incidence rates among the 10 studies were all within a narrow range, from 0 per 100 person-years at risk to 2.96 per 100 person-years at risk. In 9 of the 10 studies, the observed incidence rate was less than 2 per 100 person-years at risk. The weighted average incidence rate was 0.7 per 100 person-years at risk. CONCLUSIONS: The recent incidence rate in New York City is quite low for a high-seroprevalence population of injection drug users. The very large HIV epidemic among injection drug users in New York City appears to have entered a "declining phase," characterized by low incidence and declining prevalence. The data suggest that very large high-seroprevalence HIV epidemics may be "reversed."
Authors: D C Des Jarlais; S R Friedman; M Marmor; H Cohen; D Mildvan; S Yancovitz; U Mathur; W el-Sadr; T J Spira; J Garber Journal: AIDS Date: 1987-07 Impact factor: 4.177
Authors: D C Des Jarlais; S R Friedman; D M Novick; J L Sotheran; P Thomas; S R Yancovitz; D Mildvan; J Weber; M J Kreek; R Maslansky Journal: JAMA Date: 1989-02-17 Impact factor: 56.272
Authors: D C Des Jarlais; S R Friedman; J L Sotheran; J Wenston; M Marmor; S R Yancovitz; B Frank; S Beatrice; D Mildvan Journal: JAMA Date: 1994-01-12 Impact factor: 56.272
Authors: M Marmor; S Titus; H Wolfe; K Krasinski; R Maslansky; M Simberkoff; S Beatrice; S Nichols; D C Des Jarlais Journal: AIDS Res Hum Retroviruses Date: 1994 Impact factor: 2.205
Authors: C Des Jarlais; T Perlis; S R Friedman; T Chapman; J Kwok; R Rockwell; D Paone; J Milliken; E Monterroso Journal: Am J Public Health Date: 2000-07 Impact factor: 9.308
Authors: Carey B Maslow; Samuel R Friedman; Theresa E Perlis; Russell Rockwell; Don C Des Jarlais Journal: Am J Public Health Date: 2002-03 Impact factor: 9.308
Authors: Sabriya L Linton; Hannah L F Cooper; Mary E Kelley; Conny C Karnes; Zev Ross; Mary E Wolfe; Yen-Tyng Chen; Samuel R Friedman; Don Des Jarlais; Salaam Semaan; Barbara Tempalski; Catlainn Sionean; Elizabeth DiNenno; Cyprian Wejnert; Gabriela Paz-Bailey Journal: Ann Epidemiol Date: 2016-08-08 Impact factor: 3.797